What is NanoString?
Headquartered in Seattle, Washington, NanoString Technologies is a specialized provider of advanced life science tools designed to facilitate complex translational research. The company's core competency lies in its ability to provide high-resolution, multiplexed analysis of gene and protein expression, which is essential for modern drug discovery and clinical diagnostics. By bridging the gap between basic research and clinical application, NanoString has established itself as an indispensable partner for academic institutions, pharmaceutical companies, and clinical laboratories worldwide. Its market position is defined by a unique combination of proprietary technology and a deep understanding of the evolving needs within the precision medicine landscape.
How much funding has NanoString raised?
NanoString has raised a total of $983.4M across 16 funding rounds:
Stock Offering
$54M
Stock Offering
$57M
Debt
$45M
Stock Offering
$56.5M
Stock Offering
$46.8M
Debt
$100M
Stock Offering
$68.3M
Debt
$200M
Stock Offering
$215.7M
Other Financing Round
$47.5M
Stock Issuance/Offering (2013): $54M led by Undisclosed
Stock Issuance/Offering (2014): $57M supported by Undisclosed
Debt (2014): $45M featuring Capital Royalty
Stock Issuance/Offering (2017): $56.5M backed by Undisclosed
Stock Issuance/Offering (2018): $46.8M with participation from Undisclosed
Debt (2018): $100M led by CR Group
Stock Issuance/Offering (2019): $68.3M supported by Undisclosed
Debt (2020): $200M featuring Undisclosed
Stock Issuance/Offering (2020): $215.7M backed by Undisclosed
Other Financing Round (2024): $47.5M, investors not publicly disclosed
Key Investors in NanoString
Draper Fisher Jurvetson
A prominent venture capital firm with a global footprint, DFJ focuses on identifying and funding extraordinary entrepreneurs across diverse sectors, including life sciences and technology.
OVP Venture Partners
A Pacific Northwest-based venture firm specializing in early-stage investments within digital biology, cleantech, and information technology sectors.
Clarus Ventures
Now part of Blackstone Life Sciences, this firm focuses on late-stage development of innovative medical products to address critical gaps in the life sciences market.
What's next for NanoString?
With the successful completion of its most recent strategic financing, NanoString is well-positioned to accelerate its product development roadmap and deepen its market penetration. The company is expected to leverage this capital to enhance its existing suite of analytical tools, potentially focusing on the integration of artificial intelligence to streamline data interpretation for researchers. Furthermore, the firm will likely prioritize the expansion of its commercial footprint in key international markets, aiming to capitalize on the growing demand for high-throughput molecular profiling. As the life sciences sector continues to prioritize personalized therapeutic approaches, NanoString's strategic focus on scalable, high-impact technology will be pivotal in maintaining its competitive advantage and driving long-term value for its stakeholders.
See full NanoString company page
